Neurogene NGNE
NASDAQ NGNE
$25.10 -0.18 (-0.71%)
At close: Nov 11, 2026 · 4:00 PM EST

Neurogene (NGNE) Asset Writedowns and Impairment (2024 - 2025)

Updated

Neurogene (NGNE) recorded Asset Writedowns and Impairment of $120,000 in Q4 2025.

Analysis

Neurogene (NGNE) Asset Writedowns and Impairment (2024 - 2025) Analysis & Trends

  • Across earlier years, Asset Writedowns and Impairment came in at $91,000 in FY2024.
  • The Q4 2025 figure is the lowest quarterly Asset Writedowns and Impairment since Q1 2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Neurogene 700.15 Mn -397.16 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 120,000.00
Mar 31, 2024 91,000.00
API Access

Neurogene Asset Writedowns and Impairment API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=asset-writedowns-and-impairment&ticker=NGNE&period=max&api_key=YOUR_API_KEY